Former Roche exec Barron to head R&D at Google's Calico

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Former Roche exec Barron to head R&D at Google's Calico

Google's ($GOOG) new biotech outfit Calico, headed by former Genentech CEO Art Levinson, picked up another fellow Roche ($RHHBY) alum, Hal Barron, formerly CMO at Genentech. Barron joins the R&D team at Calico, which is compiling a who's who of industry players to focus on the company's vague goal to research the aging arena. More

Google's Calico
Hal Barron will head R&D.


Genocea Biosciences
Katrine Bosley will serve as chairman of the board.


Biotech

> Genocea Biosciences has named Katrine Bosley as chairman of its board of directors. Release

Bioheart President and CEO Mike Tomas will head the advisory board at the eMerge Americas technology showcase. Release

Along with its acquisition of Silverstone Solutions, BiologicTx appointed David Jacobs as its chief technology officer. Release

Transgenomic named Stephen Miller as the company's senior vice president and general manager of its patient testing business unit. Release

InVivo Therapeutics named Christopher McNulty as vice president of business development. Release

Stellar Biotechnologies appointed Mark McPartland as its vice president of corporate development and communications. Release

Cannabis Science bumped Robert Kane up to the position of chief financial officer. Release

Galena BioPharma has appointed Dr. Brian Hamilton as executive vice president and chief medical officer. Release

Pharma

Bristol-Myers Squibb ($BMY) added several new executive positions: Giovanni Cafario will be executive vice president and chief commercial officer, Charles Bancroft will take on additional duties in business development and strategy, Murdo Gordon will serve as president in the U.S. and Beatrice Cazala, who has been serving as executive vice president of commercial operations, is "in the process of transitioning to a new role within the company." Story | Release

Camargo Pharmaceutical Services named Jim Beach as the company's new chief operating officer. Release

Lithera brought on Dr. Lincoln Krochmal as chief medical officer. Prior to joining Lithera, Krochmal was president and CEO of Excaliard Pharmaceuticals, an aesthetics company acquired by Pfizer ($PFE). Release

Antares Pharma ($ATRS) appointed David Bergstrom to the position of senior vice president of pharmaceutical development. Bergstrom comes to Antares Pharma from Advantar Laboratories, where he was the executive vice president and chief operating officer. Release

Dr. Juergen Froehlich joined Aradigm as chief medical officer. Previously, he was the head of regulatory affairs for Vertex Pharmaceuticals ($VRTX). Release

Retrophin has added several new faces to its executive management team, including Maria Beconi as vice president of preclinical development; Ronald Guido as vice president of regulatory affairs; Jennifer Hunt as vice president of clinical operations; Nils Olsson as vice president of chemistry, manufacturing and control; Ryan Bucco as director of medical strategy; and Kristyn Bogli as director of clinical logistics. Release

Adrian Raiche joined Coldstream Laboratories as the company's director of formulation development. Release

CRO

NMS Labs appointed Pierre Cassigneul as president and CEO. Cassigneul most recently served as president and CEO of Predictive Biosciences. Release

Gail Fowler joined Rho as vice president of operations. Fowler's most recent position was vice president of clinical operations and clinical trial management for Icon ($ICLR). Release

Nigel Ramsden joined Synthesis Med Chem as the head of its European operations. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.